HOME >
IBL News >
Licensing Opportunity: - Novel Drug Seeds: Monoclonal Antibody for anti-SFTS-virus

IBL News

Events / Others

Events / Others2023/08/07: Licensing Opportunity: - Novel Drug Seeds: Monoclonal Antibody for anti-SFTS-virus

Related Materials

SFTS_ACT101_out-licensing（1 MB）

Monoclonal Antibody for anti-SFTS-virus

We have been actively looking for candidates who wish to acquire a novel drug seeds (anti-SFTSV antibody as drug seeds - ACT101) for fulfilling unmet medical needs of SFTS (Severe Fever with Thrombocytopenia Syndrome).

SFTS

SFTS is thermal hemorrhagic disease, caused by infection with SFTS virus (SFTSV) carried by ticks and it is categorized as rare disease.

There is critical demand for drug development in south east Asian countries such as China, South Korea, Japan, Indonesia etc. since the fatality rate of SFTS is high and there is no effective basic treatment so far.

We have the following test reports.

- In vitro efficacy for SFTSV isotypes
- In vivo efficacy of other animal models and single dose toxicity test.

Reference

An anti-Gn glycoprotein antibody from a convalescent patient potently inhibits the infection of severe fever with thrombocytopenia syndrome virus. Kim KH et al. PLoS Pathog. 2019 Feb 1;15(2):e1007375.

We are open for discussion with any candidates who are interested in for the acquisition of the drug seeds.

Please feel free to contact us.

Sales Department
Antibody related Business Division
Immuno-Biological Laboratories Co., Ltd.
Email: do-ibl@ibl-japan.co.jp

Return to IBL News Top